Overview

Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
To define the maximum tolerated dose of oral daily ENMD 2076 in patients with relapsed or refractory hematological malignancies
Phase:
Phase 1
Details
Lead Sponsor:
CASI Pharmaceuticals, Inc.